title: Expression and pharmacology of endogenous Cav channels in SH-SY5Y human neuroblastoma cells.
abstract: SH-SY5Y human neuroblastoma cells provide a useful in vitro model to study the mechanisms underlying neurotransmission and nociception. These cells are derived from human sympathetic neuronal tissue and thus, express a number of the Cav channel subtypes essential for regulation of important physiological functions, such as heart contraction and nociception, including the clinically validated pain target Cav2.2. We have detected mRNA transcripts for a range of endogenous expressed subtypes Cav1.3, Cav2.2 (including two Cav1.3, and three Cav2.2 splice variant isoforms) and Cav3.1 in SH-SY5Y cells; as well as Cav auxiliary subunits α2δ1-3, β1, β3, β4, γ1, γ4-5, and γ7. Both high- and low-voltage activated Cav channels generated calcium signals in SH-SY5Y cells. Pharmacological characterisation using ω-conotoxins CVID and MVIIA revealed significantly (∼ 10-fold) higher affinity at human versus rat Cav2.2, while GVIA, which interacts with Cav2.2 through a distinct pharmacophore had similar affinity for both species. CVID, GVIA and MVIIA affinity was higher for SH-SY5Y membranes vs whole cells in the binding assays and functional assays, suggesting auxiliary subunits expressed endogenously in native systems can strongly influence Cav2.2 channels pharmacology. These results may have implications for strategies used to identify therapeutic leads at Cav2.2 channels.
authors.affiliation: Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Australia.
authors.forename: Silmara R
authors.initials: SR
authors.lastname: Sousa
authors.forename: Irina
authors.initials: I
authors.lastname: Vetter
authors.forename: Lotten
authors.initials: L
authors.lastname: Ragnarsson
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lewis
mesh_terms: D001667:Binding, Competitive; D002121:Calcium Channel Blockers / Q000378:metabolism; D015220:Calcium Channels / Q000235:genetics* / Q000378:metabolism*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism*; D011485:Protein Binding; D020033:Protein Isoforms; D020866:omega-Conotoxin GVIA / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020033:Protein Isoforms; D020866:omega-Conotoxin GVIA
references.citation: J Biol Chem. 2000 Nov 10;275(45):35335-44
references.pmid: 10938268
references.citation: J Biol Chem. 2004 Aug 13;279(33):34705-14
references.pmid: 15166237
references.citation: Cell Calcium. 1997 Oct;22(4):299-311
references.pmid: 9481480
references.citation: J Mol Recognit. 2000 Mar-Apr;13(2):55-70
references.pmid: 10822250
references.citation: J Neurosci. 2002 Aug 15;22(16):6939-52
references.pmid: 12177192
references.citation: Curr Opin Neurobiol. 2009 Jun;19(3):237-44
references.pmid: 19559597
references.citation: J Neurosci. 1991 Feb;11(2):435-44
references.pmid: 1992011
references.citation: Brain Res. 1993 Feb 12;603(1):64-73
references.pmid: 7680940
references.citation: Annu Rev Biochem. 1994;63:823-67
references.pmid: 7979255
references.citation: J Biol Chem. 2001 May 11;276(19):15728-35
references.pmid: 11279062
references.citation: Neuropharmacology. 2000;39(1):1-10
references.pmid: 10665814
references.citation: Gen Pharmacol. 1995 Oct;26(6):1191-201
references.pmid: 7590107
references.citation: Anal Biochem. 1990 Jan;184(1):67-73
references.pmid: 2157351
references.citation: Assay Drug Dev Technol. 2010 Dec;8(6):685-94
references.pmid: 21050074
references.citation: Pharmacol Rev. 2003 Dec;55(4):575-8
references.pmid: 14657413
references.citation: Gen Physiol Biophys. 2005 Jun;24 Suppl 1:1-78
references.pmid: 16096350
references.citation: Neuron. 1992 Jan;8(1):71-84
references.pmid: 1309651
references.citation: Neuron. 1997 Jan;18(1):153-66
references.pmid: 9010213
references.citation: Pharmacol Rev. 2012 Apr;64(2):259-98
references.pmid: 22407615
references.citation: Neurochem Int. 2006 Aug;49(3):256-61
references.pmid: 16574279
references.citation: Pain. 2012 Jan;153(1):245-249
references.pmid: 22082570
references.citation: Neurochem Int. 2004 Oct;45(5):583-95
references.pmid: 15234100
references.citation: J Neurophysiol. 1998 Jan;79(1):240-52
references.pmid: 9425195
references.citation: Nature. 1985 Aug 1-7;316(6027):440-3
references.pmid: 2410796
references.citation: Clin J Pain. 2010 Sep;26(7):635-44
references.pmid: 20639730
references.citation: Annu Rev Cell Dev Biol. 2000;16:521-55
references.pmid: 11031246
references.citation: J Pharmacol Exp Ther. 2000 Oct;295(1):302-8
references.pmid: 10991994
references.citation: Exp Brain Res. 2002 Dec;147(4):456-63
references.pmid: 12444477
references.citation: Biochem Pharmacol. 2012 Jun 1;83(11):1562-71
references.pmid: 22410003
references.citation: Mol Pharmacol. 1998 Jun;53(6):1104-11
references.pmid: 9614215
references.citation: Mol Pharmacol. 1995 Sep;48(3):540-9
references.pmid: 7565636
references.citation: Assay Drug Dev Technol. 2008 Apr;6(2):195-212
references.pmid: 18471074
references.citation: Eur J Neurosci. 1994 Jun 1;6(6):943-52
references.pmid: 7952281
references.citation: Neuron. 2004 Jan 8;41(1):127-38
references.pmid: 14715140
references.citation: Cell Mol Neurobiol. 2007 Nov;27(7):901-8
references.pmid: 17934806
references.citation: J Neurosci. 1988 Sep;8(9):3354-9
references.pmid: 2845019
references.citation: J Biol Chem. 2001 Aug 31;276(35):32917-24
references.pmid: 11441000
references.citation: Science. 1992 Jul 17;257(5068):389-95
references.pmid: 1321501
references.citation: BMC Bioinformatics. 2012 Jun 18;13:134
references.pmid: 22708584
references.citation: Cell Mol Life Sci. 2000 Mar;57(3):514-20
references.pmid: 10823251
references.citation: Brain Res Mol Brain Res. 1990 Aug;8(3):263-6
references.pmid: 2170805
references.citation: Brain Res. 1988 Jun 21;453(1-2):247-56
references.pmid: 3401762
references.citation: J Neurosci. 2008 Oct 15;28(42):10604-17
references.pmid: 18923037
references.citation: J Neurochem. 1995 Jun;64(6):2544-51
references.pmid: 7760034
references.citation: Curr Opin Neurobiol. 2003 Jun;13(3):298-307
references.pmid: 12850214
references.citation: Channels (Austin). 2007 Jul-Aug;1(4):225-7
references.pmid: 18708749
references.citation: Mol Neurobiol. 2002 Aug;26(1):21-44
references.pmid: 12392054
references.citation: Mol Pharmacol. 2010 Feb;77(2):139-48
references.pmid: 19892914
references.citation: Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a003947
references.pmid: 21746798
references.citation: EMBO J. 2002 Apr 2;21(7):1514-23
references.pmid: 11927536
references.citation: Eur J Neurosci. 2006 Aug;24(3):709-18
references.pmid: 16930401
references.citation: Sci STKE. 2004 Oct 05;2004(253):re15
references.pmid: 15467096
references.citation: J Neurosci. 2002 Jan 1;22(1):82-92
references.pmid: 11756491
references.citation: Eur J Neurosci. 2007 Jan;25(2):435-44
references.pmid: 17284184
references.citation: Toxicon. 2007 Feb;49(2):124-41
references.pmid: 17239913
references.citation: Biochem Pharmacol. 2006 Sep 14;72(6):770-82
references.pmid: 16844100
references.citation: J Pharmacol Exp Ther. 1999 Nov;291(2):464-73
references.pmid: 10525060
references.citation: Neuron. 2004 Jan 8;41(1):3-4
references.pmid: 14715128
references.citation: Neuroscience. 2001;105(3):599-617
references.pmid: 11516827
references.citation: J Mol Biol. 1990 Oct 5;215(3):403-10
references.pmid: 2231712
references.citation: Assay Drug Dev Technol. 2007 Apr;5(2):191-203
references.pmid: 17477828
references.citation: Neuropharmacology. 1993 Nov;32(11):1089-102
references.pmid: 8107964